HUM · Q3 2025 Earnings

Neutral

Humana

Reported November 5, 2025

30-second summary

Humana posted Q3 revenue of $32.65B (+11.1% YoY) and adjusted EPS of $3.24, with the Insurance segment benefit ratio at 91.1% — in line with management's previously disclosed "just above 91 percent" expectation for the quarter. The FY non-GAAP EPS guide was affirmed at ~$17.00 and the FY benefit-ratio range was affirmed at 90.1–90.5% (YTD is 89.3%, inside the range). FY GAAP EPS was reduced by $1.51 to ~$12.26, driven by non-operational items (loss on sale of business, value creation initiatives, put/call adjustments) rather than core performance. The individual MA membership decline was narrowed to ~425k (from "up to 500k") on stronger retention and better-than-expected sales. The tension on this print is the consolidated operating cost ratio (GAAP) running at 12.6% in Q3, with the FY GAAP guide formally raised to 11.6–12.1% (from 11.3–11.7%), even as the non-GAAP operating cost ratio guide is held at 11.3–11.7%.

Headline numbers

EPS

Q3 FY2025

$3.24

Revenue

Q3 FY2025

$32.65B

+11.1% YoY

Operating margin

Q3 FY2025

1.2%

Key financials

Q3 FY2025

Metric	Q3 FY2025	YoY	Q2 FY2025	QoQ
Revenue	$32.65B	+11.1%	$32.39B	+0.8%
EPS	$3.24	—	$6.27	-48.3%
Operating margin	1.2%	—	—	—

Guidance

Affirmed non-GAAP EPS at $17.00 but cut GAAP EPS by 11% to $12.26; modestly improved Medicare Advantage membership decline guidance from up-to-500k to approximately 425k members.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Changes to prior guidance

Metric	Period	Prior guide	New guide	Δ	Result
GAAP EPS	FY 2025	approximately $13.77	approximately $12.26	-$1.51 per share	Lowered
Individual Medicare Advantage Membership Decline	FY 2025	decline of up to 500,000 members	approximately 425,000 members	75,000 fewer members declining than prior guidance	Raised
CenterWell Primary Care Net Patient Growth	FY 2025	50,000 to 70,000	approximately 56,600+ (year-to-date through Q3)	Tracking ahead of the midpoint (60k) of prior range; 56.6k YTD represents strong progress	Raised

Reaffirmed unchanged this quarter: Insurance Segment Benefit Ratio (90.1% to 90.5%), Adjusted (Non-GAAP) EPS (approximately $17.00)

Segment KPIs

Q3 FY2025

Segment	Q3 FY2025	YoY
Insurance	$31.189B	+9.9%
CenterWell	$5.879B	+16.6%
Individual Medicare Advantage	$22.456B	+2.7%
Group Medicare Advantage	$2.24B	+17.1%
Medicare stand-alone PDP	$1.755B	+143.4%
State-based contracts and other	$3.729B	+27.7%

Other KPIs

Q3 FY2025

Segment	Q3 FY2025
Insurance Segment Benefit Ratio	91.1%
Consolidated Benefit Ratio	91.1%
Insurance Segment Operating Cost Ratio	9.1%
Consolidated Operating Cost Ratio	12.6%
CenterWell Operating Cost Ratio	93.9%
Days in Claims Payable	33.2 days
Individual Medicare Advantage Membership Change (FY 2025 guidance)	Decline of approximately 425,000 members
CenterWell Primary Care Patient Growth	56,600 patients (+15% YTD vs Dec 31, 2024)

Management tone

Cautious cost-trend silence (Q2) → operational pivot to retention and LTV (Q3).

A full multi-quarter tone arc is constrained by Q3 transcript availability — only the Q&A and a portion of prepared remarks were accessible. The shifts below are anchored in what was available.

The Q3 narrative leads with affirmation: non-GAAP EPS at ~$17.00, benefit-ratio range at 90.1–90.5%, and the FY revenue floors all reaffirmed verbatim in the Projections page. Management's chosen emphasis is membership retention (425k decline vs. 500k) and the CenterWell patient and pharmacy momentum. The one explicit guidance worsening is the consolidated GAAP operating cost ratio, raised to 11.6–12.1%, which management ties to value creation initiative charges and business mix toward CenterWell.

David Dittenfoss's framing that growth is "an outcome of optimizing lifetime value and NPV" rather than a target, paired with refusal to give Andrew Mock or Justin Lake a quantitative new-membership range, signals that management does not want to be held to a 2026 enrollment number two weeks into AEP. Joshua Raskin's question pulled the most strategically loaded answer: Dittenfoss called the LTV/NPV emphasis an evolution and explicitly framed the integrated insurance + CenterWell model as central, with willingness to balance long-term enterprise value against quarterly delivery. Celeste Mellet added the qualifier that long-term focus does not displace short-term delivery — a notable hedge.

The handling of fully-capitated provider relationships in Q&A is the other notable shift. George Renaudin described taking Part D risk back from value-based partners due to IRA cost shifts, completing a two-year benefit-reduction cycle to "reset" product margins, and implementing STARS mitigation programs with value-based partners — characterizing the relationships as collaborative with no significant pushback.

Q&A highlights

Andrew Mock · Barclays

Can you provide a framework for the level of new membership growth before it impacts operational capacity, and are you already pulling levers to manage growth?

David Dittenfoss explained that growth is an outcome of optimizing lifetime value and NPV. The company is balancing appropriate pricing, stable plan margins, customer experience, and operational differentiation. They are not sharing specific growth numbers because operational capacity varies by member mix, product mix, and channel mix. Management is working dynamically to balance new member growth with ability to serve members, having made adjustments heading into AEP and continuing to monitor OEP and rest-of-year dynamics.

Focus on lifetime value and NPV as primary objective, not raw membership growthStabilizing margins across all plans to avoid low-margin high-growth cyclesCommitted to much better retention than Investor Day targetsNot sharing specific operational capacity numbers due to multiple dynamic variables

Justin Lake · Wolf Research

What is the expected range for new membership growth? What are the percentages of fully capitated agreements in MA, and what pushback are you experiencing from providers on benefit reductions?

Jim and George declined to provide specific new membership growth numbers, reiterating that mix matters more than a single number. On fully capitated agreements, George discussed mitigation actions including taking Part D risk back due to IRA shifts, reducing benefits over two years to reset the product, and implementing STARS mitigation programs. The company reported feeling good about provider relationships and said there is no significant pushback; instead, providers are working collaboratively on contract changes.

Part D risk being taken back due to IRA cost shiftsTwo-year benefit reduction cycle completed to reset product marginsSTARS mitigation programs implemented with value-based partnersDaily field engagement with providers on contract changes

Joshua Raskin · Nefron Research

Is the focus on LTV/NPV a strategic shift? Are you willing to accept different margin levels in insurance to create margin through CenterWell?

David Dittenfoss characterized the LTV/NPV focus as an evolution, not entirely new. The company is attempting to get all insurance products to reasonable margins rather than cycling between low-margin high-growth and margin-recovery phases. The integrated health model across insurance and CenterWell is increasingly central to the strategy. Management emphasized balancing long-term value creation with short-term quarterly/annual delivery.

LTV/NPV focus described as evolution of existing strategyGoal to eliminate low-margin high-growth products from portfolioIntegrated health across insurance and CenterWell central to long-term valueMulti-year view toward lifetime value informing product approach

Scott Fidel · Goldman Sachs

What is the product mix (PPO, HMO, DSNP) of new MA sales, and where is PDP growth coming from?

David Dittenfoss said it is too early (only a few weeks into AEP) to parse product mix details, but indicated healthy growth across all segments with no disproportionate concentration in any one segment and no geographic distortion in competitor exit areas. George Ruttedon reported strong PDP growth driven by basic and value plans, with significant auto-enrollment pickup due to being below the benchmark in twice as many states as 2025, which will include competitive reassignments.

New MA sales growth across all product segments, none disproportionateNo distortion in geographies including Plex marketsSignificant PDP growth from basic and value plansBelow benchmark in approximately twice as many states as 2025

Answers to last quarter's watch list

STARS Plan Preview 1 results post-October CMS release — Bonus year 27 results were "disappointing but not surprising" and consistent with management's baseline planning scenario; bonus year 28 trajectory described as showing meaningful YoY improvement across the majority of metrics, with 600k more gaps closed YoY. Management declined to speculate on thresholds.

Continue monitoring

Insurance segment benefit ratio trajectory toward the 90.1–90.5% FY guide — Resolved as guided. Q3 91.1% printed in line with the pre-disclosed "just above 91%" expectation, YTD is 89.3% (inside the range), and the FY range was affirmed. The implied Q4 step-up reflects normal seasonality plus the IRA-driven Part D mix shift. Status: Resolved as guided.

MA membership decline finalization — Narrowed to ~425k from "up to 500k" — roughly 75k better than prior, driven by stronger retention and better-than-expected sales.

Resolved positively

CenterWell Pharmacy GLP-1 partnership economics — CenterWell segment revenue grew 16.6% in Q3, an acceleration from 11.9% in Q2, consistent with continued specialty/GLP-1 momentum. However, the CenterWell operating cost ratio of 93.9% implies thin segment margins, and management did not break out GLP-1 economics specifically. Acceleration confirmed; margin accretion not confirmed.

Continue monitoring

RAD-V audit and CMS callback exposure — No disclosure in the Q3 press release; not raised in the available Q&A.

Continue monitoring

CenterWell Primary Care net patient growth — YTD growth of 56,600 puts Humana solidly within the affirmed 50,000–70,000 FY guide range with a quarter to go, tracking ahead of the midpoint.

Resolved positively

What to watch into next quarter

Q4 Insurance benefit ratio mechanics — with Q3 at 91.1% (pre-guided) and YTD at 89.3% (inside the affirmed FY range), Q4 needs to print in the ~92.5–93.7% zone to land FY at 90.1–90.5%. Watch whether IRA Part D seasonality and the state-based/PDP mix produce that step-up cleanly or whether the FY range is revisited.

Consolidated GAAP operating cost ratio in Q4 — with the FY GAAP guide formally raised to 11.6–12.1% and Q3 GAAP at 12.6%, Q4 needs material improvement to land inside the new range. The size of further value creation initiative charges in Q4 will be the swing factor.

AEP and 2026 MA membership disclosure on the Q4 call — management explicitly refused to give 2026 enrollment ranges in Q3 Q&A. Watch whether they break the silence by Q4, and whether the disclosed range implies growth, flat, or further decline.

STARS bonus year 28 trajectory — management cited improvement across HEDIS and patient safety metrics but noted CAHPS, HOS, and TTY measures still to be assessed in 1H26. The hybrid season completion in Q2 2026 is when management said they would share more.

Days in claims payable trajectory — DCP fell 3.3 days QoQ to 33.2. Management framed this as timing/mix; watch whether Q4 sees further compression or a rebuild and whether IBNR continues to track stable.

Whether the GAAP/non-GAAP EPS gap widens further — non-GAAP held at $17.00 while GAAP was cut by $1.51 this quarter on non-operational items. Watch the size and nature of value creation and put/call adjustments in Q4 for whether the gap reflects discrete items or a structural reset.

Sources

Humana Q3 2025 detailed press release (8-K Ex. 99.2): https://www.sec.gov/Archives/edgar/data/49071/000004907125000055/hum-2025q38kxex99x2detailed.htm
Humana Q3 2025 earnings call prepared remarks and Q&A transcript, Humana Investor Relations: https://humana.gcs-web.com/financial-information/quarterly-results

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.